Public research preview
Gilbert Cisneros, Representative disclosure: Cytokinetics, Incorporated - Common Stock (CYTK)
Disclosed a buy transaction in Cytokinetics, Incorporated - Common Stock (CYTK). Use this page to inspect source evidence, confidence scores, filing delay, and post-disclosure price movement before deciding whether to research the signal further.
This public page is for public-disclosure research only. It is not investment advice and does not place orders. Verify the official source before relying on any signal.
Evidence passport
Official-source context and parser confidence before any simulation or alert decision.
- Source
- House STOCK Act disclosures
- Published
- 18 Nov 2025, 00:00
- Parser confidence
- 94%
- Instrument mapping
- 95%
- Filing delay
- 40 days
Timeline
Transaction date
9 Oct 2025
Public disclosure
18 Nov 2025
Now
Tracked today
Filing delay: 40 days
Price movement
Complete coverage
- Provider
- Yahoo Finance daily close
- Fetched
- 3 Jul 2026
Stock path
CYTK from pre-transaction context through latest close.
Bought
9 Oct 2025 · 60.31 USD · Not public yet
System decision
Would not buy — The strategy's filters reject this signal. Failed filters: Filed within 30 days.
- Not public yet
- Would not buy
- Observed transaction close
- 60.31
- Observed disclosure close
- 66.16
- Observed latest close
- 86.49
- Pre-disclosure move
- +9.7%
- Post-disclosure move
- +30.7%
- Market-adjusted move
- +17.0%
- Pre-disclosure peak run-up
- +11.0%
- Retrace from peak
- -1.2%
Why Copy Window is Probably too late
Supporting factors
- Parsed buy disclosure for ordinary shares from House STOCK Act disclosures.
- Reported amount is $1,001 - $15,000.
- Post-disclosure move is calculated from Yahoo Finance daily close daily closes.
Cautions
- Yahoo Finance daily close coverage is end-of-day and should be verified against the official price source.
- Review the original source document before making any investment decision.
Source document
House STOCK Act disclosures, published 18 Nov 2025, 00:00
- Parser confidence
- 94%
- Instrument mapping
- 95%